Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.
The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.
Trinity plans to bring to market in 2025 Metabolomics Diagnostics' PrePsia test that can be used to determine preeclampsia risk in the 12th week of pregnancy.
NEW YORK – The Alzheimer's Drug Discovery Foundation on Wednesday announced that it has invested $7.0 million in Alzheimer's disease diagnostic company C2N Diagnostics. Already have a 360Dx or ...
The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.
NEW YORK — Protean BioDiagnostics has signed an agreement to market Nanostics' prostate cancer risk assessment tool in the US, the companies said Tuesday. Called ClarityDx Prostate, the tool analyzes ...